Unknown

Dataset Information

0

Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.


ABSTRACT: Epichaperome network maintenance is vital to survival of tumors that express it. PU-H71 is an epichaperome inhibitor that binds to the ATP-binding site of HSP90 and has demonstrated antitumor activity in breast cancer xenograft models and clinical safety in patients. PU-positron emission tomography (PET) is a theragnostic imaging tool that allows visualization of the epichaperome target. In this phase Ib trial, we present safety and tolerability for PU-H71 plus nab-paclitaxel in HER2-negative patients with metastatic breast cancer (MBC) and the utility of PU-PET as a noninvasive predictive biomarker. We performed a 3 + 3 dose-escalation study with escalating PU-H71 doses and standard nab-paclitaxel. The primary objective was to establish safety and determine maximum tolerated dose (MTD)/recommended phase 2 dose. Secondary objectives were to assess pharmacokinetics and clinical efficacy. Patients could enroll in a companion PU-PET protocol to measure epichaperome expression before treatment initiation to allow exploratory correlation with treatment benefit. Of the 12 patients enrolled, dose-limiting toxicity occurred in one patient (G3 neutropenic fever) at dose level 1; MTD of PU-H71 was 300 mg/m2 plus nab-paclitaxel 260 mg/m2 administered every 3 weeks. Common toxicities included diarrhea, fatigue, peripheral neuropathy, and nausea. PU-H71 systemic exposure was not altered by nab-paclitaxel administration. Two of 12 patients had partial response (overall response rate, 17%) and the clinical benefit rate was 42% (5 of 12). Time to progression was associated with baseline epichaperome positivity and PU-H71 peak standard uptake value (SUV), with more durable disease control observed with high epichaperome levels. The combination of PU-H71 and nab-paclitaxel was well tolerated, with evidence of clinical activity. More durable disease control without progression was observed in patients with high baseline epichaperome expression. A phase II trial of this combination with PU-PET as a companion diagnostic for patient selection is currently planned.

SUBMITTER: Jhaveri KL 

PROVIDER: S-EPMC7713524 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.

Jhaveri Komal L KL   Dos Anjos Carlos H CH   Taldone Tony T   Wang Rui R   Comen Elizabeth E   Fornier Monica M   Bromberg Jacqueline F JF   Ma Weining W   Patil Sujata S   Rodina Anna A   Pillarsetty Nagavarakishore N   Duggan Susan S   Khoshi Sarhe S   Kadija Nathan N   Chiosis Gabriela G   Dunphy Mark P MP   Modi Shanu S  

JCO precision oncology 20201117


<h4>Purpose</h4>Epichaperome network maintenance is vital to survival of tumors that express it. PU-H71 is an epichaperome inhibitor that binds to the ATP-binding site of HSP90 and has demonstrated antitumor activity in breast cancer xenograft models and clinical safety in patients. PU-positron emission tomography (PET) is a theragnostic imaging tool that allows visualization of the epichaperome target. In this phase Ib trial, we present safety and tolerability for PU-H71 plus nab-paclitaxel in  ...[more]

Similar Datasets

| S-EPMC6126370 | biostudies-literature
| S-EPMC11640441 | biostudies-literature
| S-EPMC4779400 | biostudies-literature
| S-EPMC4803456 | biostudies-literature
| S-EPMC10769796 | biostudies-literature
2011-11-01 | GSE21217 | GEO
2015-02-09 | E-MTAB-3175 | biostudies-arrayexpress
| S-EPMC2699564 | biostudies-literature
| S-EPMC10529370 | biostudies-literature
| S-EPMC3954645 | biostudies-literature